MADISON, Wisc.—(BUSINESS WIRE)— Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), has initiated the... read more →
Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies MADISON, Wis., May 13, 2025 — Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of... read more →
MADISON, WI – April 22, 2025 – Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express™ Antibody Expression service. This new... read more →
Madison, WI – September 17, 2024 – Invenra Inc. is pleased to announce the addition of three distinguished professionals to its Board of Directors: Saira Ramasastry, Heather Preston, MD, and... read more →
Madison, WI – Aug 23, 2024 – Invenra Inc. is pleased to announce that its innovative bispecific antibody, INV724, developed for the treatment of neuroblastoma, has been awarded both Rare... read more →
MADISON, Wisc.--(BUSINESS WIRE)--Invenra’s collaboration partner, Exelixis, Inc. (NASDAQ: EXEL) has announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial of XB010 in patients with locally... read more →
Madison, WI – April 9, 2024 – Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical... read more →